Jade Biosciences, Inc.
Jade Biosciences, Inc. JBIO Peers
See (JBIO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| JBIO | $9.99 | +0.00% | 349.6M | N/A | N/A | +21.89% |
| VRTX | $445.20 | +0.00% | 116.1B | -117.75 | -$3.84 | N/A |
| REGN | $525.00 | +0.00% | 56.8B | 13.59 | $39.35 | +0.16% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $326.09 | +0.00% | 42B | -152.64 | -$2.11 | N/A |
| ARGX | $551.22 | +0.00% | 33.1B | 33.10 | $16.39 | N/A |
| BNTX | $106.47 | +0.00% | 25.8B | -29.37 | -$3.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $36.03 | +0.00% | 20.2B | 14.64 | $2.45 | +2.40% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
JBIO vs VRTX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, VRTX has a market cap of 116.1B. Regarding current trading prices, JBIO is priced at $9.99, while VRTX trades at $445.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is -117.75. In terms of profitability, JBIO's ROE is +2.01%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, JBIO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs REGN Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, REGN has a market cap of 56.8B. Regarding current trading prices, JBIO is priced at $9.99, while REGN trades at $525.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 13.59. In terms of profitability, JBIO's ROE is +2.01%, compared to REGN's ROE of +0.15%. Regarding short-term risk, JBIO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs SGEN Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, JBIO is priced at $9.99, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, JBIO's ROE is +2.01%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, JBIO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ALNY Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ALNY has a market cap of 42B. Regarding current trading prices, JBIO is priced at $9.99, while ALNY trades at $326.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is -152.64. In terms of profitability, JBIO's ROE is +2.01%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, JBIO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ARGX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ARGX has a market cap of 33.1B. Regarding current trading prices, JBIO is priced at $9.99, while ARGX trades at $551.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 33.10. In terms of profitability, JBIO's ROE is +2.01%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, JBIO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs BNTX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, BNTX has a market cap of 25.8B. Regarding current trading prices, JBIO is priced at $9.99, while BNTX trades at $106.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -29.37. In terms of profitability, JBIO's ROE is +2.01%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, JBIO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs BGNE Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, JBIO is priced at $9.99, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, JBIO's ROE is +2.01%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, JBIO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RPRX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RPRX has a market cap of 20.2B. Regarding current trading prices, JBIO is priced at $9.99, while RPRX trades at $36.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 14.64. In terms of profitability, JBIO's ROE is +2.01%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, JBIO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs DNA-WT Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, JBIO is priced at $9.99, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, JBIO's ROE is +2.01%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, JBIO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs SMMT Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, SMMT has a market cap of 15.7B. Regarding current trading prices, JBIO is priced at $9.99, while SMMT trades at $21.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -62.35. In terms of profitability, JBIO's ROE is +2.01%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, JBIO is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs INCY Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, INCY has a market cap of 13.3B. Regarding current trading prices, JBIO is priced at $9.99, while INCY trades at $68.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 343.65. In terms of profitability, JBIO's ROE is +2.01%, compared to INCY's ROE of +0.01%. Regarding short-term risk, JBIO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs UTHR Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, UTHR has a market cap of 13.1B. Regarding current trading prices, JBIO is priced at $9.99, while UTHR trades at $287.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 11.59. In terms of profitability, JBIO's ROE is +2.01%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, JBIO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs GMAB Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, GMAB has a market cap of 12.8B. Regarding current trading prices, JBIO is priced at $9.99, while GMAB trades at $20.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 12.20. In terms of profitability, JBIO's ROE is +2.01%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, JBIO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs KRTX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, JBIO is priced at $9.99, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, JBIO's ROE is +2.01%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, JBIO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs EXEL Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, JBIO is priced at $9.99, while EXEL trades at $44.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 19.92. In terms of profitability, JBIO's ROE is +2.01%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, JBIO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MRNA Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MRNA has a market cap of 11.1B. Regarding current trading prices, JBIO is priced at $9.99, while MRNA trades at $27.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -3.29. In terms of profitability, JBIO's ROE is +2.01%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, JBIO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs BMRN Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, JBIO is priced at $9.99, while BMRN trades at $54.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 20.81. In terms of profitability, JBIO's ROE is +2.01%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, JBIO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ASND Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ASND has a market cap of 10.4B. Regarding current trading prices, JBIO is priced at $9.99, while ASND trades at $172.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -25.83. In terms of profitability, JBIO's ROE is +2.01%, compared to ASND's ROE of +1.91%. Regarding short-term risk, JBIO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RXDX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, JBIO is priced at $9.99, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, JBIO's ROE is +2.01%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, JBIO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs IMGN Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, JBIO is priced at $9.99, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, JBIO's ROE is +2.01%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, JBIO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs BPMC Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, JBIO is priced at $9.99, while BPMC trades at $128.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.34. In terms of profitability, JBIO's ROE is +2.01%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, JBIO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CERE Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, JBIO is priced at $9.99, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, JBIO's ROE is +2.01%, compared to CERE's ROE of -0.43%. Regarding short-term risk, JBIO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs TECH Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, JBIO is priced at $9.99, while TECH trades at $51.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 62.75. In terms of profitability, JBIO's ROE is +2.01%, compared to TECH's ROE of +0.06%. Regarding short-term risk, JBIO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs BBIO Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, BBIO has a market cap of 8.1B. Regarding current trading prices, JBIO is priced at $9.99, while BBIO trades at $43.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -12.02. In terms of profitability, JBIO's ROE is +2.01%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, JBIO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ROIVW Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, JBIO is priced at $9.99, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, JBIO's ROE is +2.01%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, JBIO is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs VRNA Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, VRNA has a market cap of 7.7B. Regarding current trading prices, JBIO is priced at $9.99, while VRNA trades at $94.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -45.24. In terms of profitability, JBIO's ROE is +2.01%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, JBIO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ROIV Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ROIV has a market cap of 7.4B. Regarding current trading prices, JBIO is priced at $9.99, while ROIV trades at $11.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -14.59. In terms of profitability, JBIO's ROE is +2.01%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, JBIO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CORT Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, JBIO is priced at $9.99, while CORT trades at $73.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 60.27. In terms of profitability, JBIO's ROE is +2.01%, compared to CORT's ROE of +0.20%. Regarding short-term risk, JBIO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs AMRN Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, AMRN has a market cap of 6.9B. Regarding current trading prices, JBIO is priced at $9.99, while AMRN trades at $16.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas AMRN's P/E ratio is -3.82. In terms of profitability, JBIO's ROE is +2.01%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, JBIO is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RVMD Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, JBIO is priced at $9.99, while RVMD trades at $36.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -9.20. In terms of profitability, JBIO's ROE is +2.01%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, JBIO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MDGL Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MDGL has a market cap of 6.7B. Regarding current trading prices, JBIO is priced at $9.99, while MDGL trades at $302.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -16.83. In terms of profitability, JBIO's ROE is +2.01%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, JBIO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs JAZZ Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, JAZZ has a market cap of 6.6B. Regarding current trading prices, JBIO is priced at $9.99, while JAZZ trades at $106.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 14.87. In terms of profitability, JBIO's ROE is +2.01%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, JBIO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RETA Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, JBIO is priced at $9.99, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, JBIO's ROE is +2.01%, compared to RETA's ROE of +0.47%. Regarding short-term risk, JBIO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs HALO Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, HALO has a market cap of 6.5B. Regarding current trading prices, JBIO is priced at $9.99, while HALO trades at $52.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 14.07. In terms of profitability, JBIO's ROE is +2.01%, compared to HALO's ROE of +1.22%. Regarding short-term risk, JBIO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs IONS Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, IONS has a market cap of 6.4B. Regarding current trading prices, JBIO is priced at $9.99, while IONS trades at $39.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -13.36. In terms of profitability, JBIO's ROE is +2.01%, compared to IONS's ROE of -0.92%. Regarding short-term risk, JBIO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs TGTX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, JBIO is priced at $9.99, while TGTX trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 141.60. In terms of profitability, JBIO's ROE is +2.01%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, JBIO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ABCM Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, JBIO is priced at $9.99, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, JBIO's ROE is +2.01%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, JBIO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ISEE Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, JBIO is priced at $9.99, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, JBIO's ROE is +2.01%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, JBIO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs TLX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, JBIO is priced at $9.99, while TLX trades at $16.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas TLX's P/E ratio is 178.67. In terms of profitability, JBIO's ROE is +2.01%, compared to TLX's ROE of +0.14%. Regarding short-term risk, JBIO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs NUVL Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, NUVL has a market cap of 5.2B. Regarding current trading prices, JBIO is priced at $9.99, while NUVL trades at $76.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -17.65. In terms of profitability, JBIO's ROE is +2.01%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, JBIO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs AXSM Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, JBIO is priced at $9.99, while AXSM trades at $104.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -17.85. In terms of profitability, JBIO's ROE is +2.01%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, JBIO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ALKS Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, JBIO is priced at $9.99, while ALKS trades at $28.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 13.80. In terms of profitability, JBIO's ROE is +2.01%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, JBIO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ALPN Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, JBIO is priced at $9.99, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, JBIO's ROE is +2.01%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, JBIO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ADMA Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ADMA has a market cap of 4.3B. Regarding current trading prices, JBIO is priced at $9.99, while ADMA trades at $18.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ADMA's P/E ratio is 21.29. In terms of profitability, JBIO's ROE is +2.01%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, JBIO is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs PCVX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, JBIO is priced at $9.99, while PCVX trades at $32.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -8.26. In terms of profitability, JBIO's ROE is +2.01%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, JBIO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs OPT Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, JBIO is priced at $9.99, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, JBIO's ROE is +2.01%, compared to OPT's ROE of +2.60%. Regarding short-term risk, JBIO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CRSP Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CRSP has a market cap of 4.2B. Regarding current trading prices, JBIO is priced at $9.99, while CRSP trades at $48.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -10.80. In terms of profitability, JBIO's ROE is +2.01%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, JBIO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs SLNO Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, SLNO has a market cap of 4.2B. Regarding current trading prices, JBIO is priced at $9.99, while SLNO trades at $83.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas SLNO's P/E ratio is -17.43. In terms of profitability, JBIO's ROE is +2.01%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, JBIO is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RYTM Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RYTM has a market cap of 4.2B. Regarding current trading prices, JBIO is priced at $9.99, while RYTM trades at $63.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -23.37. In terms of profitability, JBIO's ROE is +2.01%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, JBIO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MRTX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, JBIO is priced at $9.99, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, JBIO's ROE is +2.01%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, JBIO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs AKRO Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, AKRO has a market cap of 4.1B. Regarding current trading prices, JBIO is priced at $9.99, while AKRO trades at $53.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -13.71. In terms of profitability, JBIO's ROE is +2.01%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, JBIO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CYTK Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CYTK has a market cap of 4B. Regarding current trading prices, JBIO is priced at $9.99, while CYTK trades at $33.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -6.36. In terms of profitability, JBIO's ROE is +2.01%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, JBIO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs KRYS Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, JBIO is priced at $9.99, while KRYS trades at $137.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 33.34. In terms of profitability, JBIO's ROE is +2.01%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, JBIO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MRUS Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MRUS has a market cap of 3.9B. Regarding current trading prices, JBIO is priced at $9.99, while MRUS trades at $52.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -12.66. In terms of profitability, JBIO's ROE is +2.01%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, JBIO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ZLAB Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, JBIO is priced at $9.99, while ZLAB trades at $34.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ZLAB's P/E ratio is -14.07. In terms of profitability, JBIO's ROE is +2.01%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, JBIO is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs PTCT Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, JBIO is priced at $9.99, while PTCT trades at $48.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.46. In terms of profitability, JBIO's ROE is +2.01%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, JBIO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RYZB Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, JBIO is priced at $9.99, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, JBIO's ROE is +2.01%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, JBIO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CBAY Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, JBIO is priced at $9.99, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, JBIO's ROE is +2.01%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, JBIO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ACAD Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, JBIO is priced at $9.99, while ACAD trades at $21.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 15.59. In terms of profitability, JBIO's ROE is +2.01%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, JBIO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ACLX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ACLX has a market cap of 3.6B. Regarding current trading prices, JBIO is priced at $9.99, while ACLX trades at $65.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -21.64. In terms of profitability, JBIO's ROE is +2.01%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, JBIO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs SWTX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, JBIO is priced at $9.99, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, JBIO's ROE is +2.01%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, JBIO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RNA Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RNA has a market cap of 3.4B. Regarding current trading prices, JBIO is priced at $9.99, while RNA trades at $28.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RNA's P/E ratio is -9.49. In terms of profitability, JBIO's ROE is +2.01%, compared to RNA's ROE of -0.27%. Regarding short-term risk, JBIO is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RARE Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RARE has a market cap of 3.4B. Regarding current trading prices, JBIO is priced at $9.99, while RARE trades at $36.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RARE's P/E ratio is -6.22. In terms of profitability, JBIO's ROE is +2.01%, compared to RARE's ROE of -1.86%. Regarding short-term risk, JBIO is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs AAPG Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, AAPG has a market cap of 3.4B. Regarding current trading prices, JBIO is priced at $9.99, while AAPG trades at $39.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas AAPG's P/E ratio is -51.99. In terms of profitability, JBIO's ROE is +2.01%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, JBIO is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs LEGN Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, JBIO is priced at $9.99, while LEGN trades at $35.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -30.75. In terms of profitability, JBIO's ROE is +2.01%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, JBIO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs SRRK Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, SRRK has a market cap of 3.2B. Regarding current trading prices, JBIO is priced at $9.99, while SRRK trades at $35.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -13.24. In terms of profitability, JBIO's ROE is +2.01%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, JBIO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs PTGX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, PTGX has a market cap of 3.1B. Regarding current trading prices, JBIO is priced at $9.99, while PTGX trades at $55.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is 64.37. In terms of profitability, JBIO's ROE is +2.01%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, JBIO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs VKTX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, JBIO is priced at $9.99, while VKTX trades at $26.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -22.99. In terms of profitability, JBIO's ROE is +2.01%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, JBIO is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MLTX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MLTX has a market cap of 3B. Regarding current trading prices, JBIO is priced at $9.99, while MLTX trades at $47.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MLTX's P/E ratio is -20.27. In terms of profitability, JBIO's ROE is +2.01%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, JBIO is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs KYMR Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, JBIO is priced at $9.99, while KYMR trades at $43.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -14.29. In terms of profitability, JBIO's ROE is +2.01%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, JBIO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MORF Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, JBIO is priced at $9.99, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MORF's P/E ratio is -14.88. In terms of profitability, JBIO's ROE is +2.01%, compared to MORF's ROE of -0.22%. Regarding short-term risk, JBIO is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MOR Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, JBIO is priced at $9.99, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MOR's P/E ratio is -12.64. In terms of profitability, JBIO's ROE is +2.01%, compared to MOR's ROE of +2.51%. Regarding short-term risk, JBIO is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MTSR Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MTSR has a market cap of 2.8B. Regarding current trading prices, JBIO is priced at $9.99, while MTSR trades at $28.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -10.58. In terms of profitability, JBIO's ROE is +2.01%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, JBIO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs IMVT Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, JBIO is priced at $9.99, while IMVT trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -5.92. In terms of profitability, JBIO's ROE is +2.01%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, JBIO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs KDNY Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, JBIO is priced at $9.99, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas KDNY's P/E ratio is -12.47. In terms of profitability, JBIO's ROE is +2.01%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, JBIO is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CRNX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, JBIO is priced at $9.99, while CRNX trades at $28.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.48. In terms of profitability, JBIO's ROE is +2.01%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, JBIO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs APGE Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, APGE has a market cap of 2.6B. Regarding current trading prices, JBIO is priced at $9.99, while APGE trades at $43.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -12.26. In terms of profitability, JBIO's ROE is +2.01%, compared to APGE's ROE of -0.19%. Regarding short-term risk, JBIO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MYOV Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, JBIO is priced at $9.99, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MYOV's P/E ratio is -14.05. In terms of profitability, JBIO's ROE is +2.01%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, JBIO is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CPRX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, JBIO is priced at $9.99, while CPRX trades at $21.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 13.50. In terms of profitability, JBIO's ROE is +2.01%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, JBIO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs XENE Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, JBIO is priced at $9.99, while XENE trades at $31.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -9.97. In terms of profitability, JBIO's ROE is +2.01%, compared to XENE's ROE of -0.32%. Regarding short-term risk, JBIO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs MIRM Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, MIRM has a market cap of 2.4B. Regarding current trading prices, JBIO is priced at $9.99, while MIRM trades at $50.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -30.06. In terms of profitability, JBIO's ROE is +2.01%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, JBIO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs PRVB Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, JBIO is priced at $9.99, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas PRVB's P/E ratio is -16.43. In terms of profitability, JBIO's ROE is +2.01%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, JBIO is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs LBPH Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, JBIO is priced at $9.99, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas LBPH's P/E ratio is -26.66. In terms of profitability, JBIO's ROE is +2.01%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, JBIO is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs DICE Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, JBIO is priced at $9.99, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas DICE's P/E ratio is -21.91. In terms of profitability, JBIO's ROE is +2.01%, compared to DICE's ROE of +0.56%. Regarding short-term risk, JBIO is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs IBRX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, JBIO is priced at $9.99, while IBRX trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -4.51. In terms of profitability, JBIO's ROE is +2.01%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, JBIO is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs APLS Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, APLS has a market cap of 2.2B. Regarding current trading prices, JBIO is priced at $9.99, while APLS trades at $17.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas APLS's P/E ratio is -9.93. In terms of profitability, JBIO's ROE is +2.01%, compared to APLS's ROE of -1.00%. Regarding short-term risk, JBIO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs ARWR Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, JBIO is priced at $9.99, while ARWR trades at $15.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -12.98. In terms of profitability, JBIO's ROE is +2.01%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, JBIO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs LGND Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, JBIO is priced at $9.99, while LGND trades at $113.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas LGND's P/E ratio is -15.44. In terms of profitability, JBIO's ROE is +2.01%, compared to LGND's ROE of -0.16%. Regarding short-term risk, JBIO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CALT Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, JBIO is priced at $9.99, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CALT's P/E ratio is -22.73. In terms of profitability, JBIO's ROE is +2.01%, compared to CALT's ROE of -1.67%. Regarding short-term risk, JBIO is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs VCYT Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, JBIO is priced at $9.99, while VCYT trades at $27.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 65.05. In terms of profitability, JBIO's ROE is +2.01%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, JBIO is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs VCEL Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, JBIO is priced at $9.99, while VCEL trades at $42.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas VCEL's P/E ratio is 832.00. In terms of profitability, JBIO's ROE is +2.01%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, JBIO is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs RXRX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, RXRX has a market cap of 2.1B. Regarding current trading prices, JBIO is priced at $9.99, while RXRX trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas RXRX's P/E ratio is -2.85. In terms of profitability, JBIO's ROE is +2.01%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, JBIO is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs NAMS Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, NAMS has a market cap of 2B. Regarding current trading prices, JBIO is priced at $9.99, while NAMS trades at $18.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -9.90. In terms of profitability, JBIO's ROE is +2.01%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, JBIO is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs DNLI Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, DNLI has a market cap of 2B. Regarding current trading prices, JBIO is priced at $9.99, while DNLI trades at $13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -5.22. In terms of profitability, JBIO's ROE is +2.01%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, JBIO is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs CGON Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, CGON has a market cap of 2B. Regarding current trading prices, JBIO is priced at $9.99, while CGON trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -17.57. In terms of profitability, JBIO's ROE is +2.01%, compared to CGON's ROE of -0.17%. Regarding short-term risk, JBIO is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs AGIO Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, AGIO has a market cap of 2B. Regarding current trading prices, JBIO is priced at $9.99, while AGIO trades at $33.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas AGIO's P/E ratio is 2.98. In terms of profitability, JBIO's ROE is +2.01%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, JBIO is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs KNSA Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, JBIO is priced at $9.99, while KNSA trades at $27.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is -113.50. In terms of profitability, JBIO's ROE is +2.01%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, JBIO is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs BCRX Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, BCRX has a market cap of 1.9B. Regarding current trading prices, JBIO is priced at $9.99, while BCRX trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas BCRX's P/E ratio is -34.62. In terms of profitability, JBIO's ROE is +2.01%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, JBIO is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.
JBIO vs BLU Comparison
JBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JBIO stands at 349.6M. In comparison, BLU has a market cap of 1.9B. Regarding current trading prices, JBIO is priced at $9.99, while BLU trades at $14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JBIO currently has a P/E ratio of N/A, whereas BLU's P/E ratio is -20.20. In terms of profitability, JBIO's ROE is +2.01%, compared to BLU's ROE of -0.22%. Regarding short-term risk, JBIO is more volatile compared to BLU. This indicates potentially higher risk in terms of short-term price fluctuations for JBIO.